Precision NanoSystems and Arcturus Therapeutics announce partnership for manufacture of nanomedicines

01 January 2015
Client work

On January 9, 2015, Precision NanoSystems, a leader in the development and application of microfluidics for the manufacture of nanomedicines; and, Arcturus Therapeutics, a leading small interfering RNA (siRNA) and messenger RNA (mRNA) drug discovery and development company, announced a partnership for the manufacture of RNA medicines.

Under the terms of the agreement, Precision’s proprietary NanoAssemblr™ platform will be used to manufacture GMP batches to support clinical studies and commercial development for RNA medicines developed using Arcturus’ proprietary LUNAR™ RNA Therapeutics platform.

Paul Armitage of Gowlings advised Precision NanoSystems with respect to the negotiation of this partnership.

NOT LEGAL ADVICE. Information made available on this website in any form is for information purposes only. It is not, and should not be taken as, legal advice. You should not rely on, or take or fail to take any action based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Gowling WLG professionals will be pleased to discuss resolutions to specific legal concerns you may have.
Related   Life Sciences, Tech, Intellectual Property

Related Insights & Resources

View all insights Related Insights & Resources
Guides
07 April 2021 The universe of pharmaceutical trademarks in Russia 2021
On-demand webinar
25 March 2021 Lifecycle of a smart idea | Commercializing artificial intelligence: Strategies for the next era of invention CLE/CPD:1 hour of substantive CPD credits with the LSO and LSBC, and may be eligible for up to 1 hour of CPD/CLE credits in other jurisdictions.
Podcasts
15 March 2021 Legally Vocal: Patrick Duxbury on his COVID-19 vaccine work and 20-year career in Life Sciences
Download or print PDF